Literature DB >> 11687754

Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease?

H H Fernandez1, J H Friedman, A J Fischman, R B Noto, M C Lannon.   

Abstract

BACKGROUND: Positron emission tomography (PET) cameras are expensive and scarce, and the tests are non-reimbursable. A less costly and more available test such as a single photon emission computed tomography (SPECT) may be helpful in the diagnosis of early or atypical Parkinson's disease (PD) if its sensitivity is comparable to a PET scan. Altropane is an iodinated form of the N-allyl analog of WIN 35,428 which acts as a dopamine transport inhibitor. When radiolabeled with the gamma emitting isotope [123I], altropane serves as a SPECT ligand with high affinity and selectivity for the dopamine transporter. It is a good marker for dopamine neurons and is useful in detecting PD.
MATERIAL AND METHODS: We describe 2 patients with typical, early PD and their [123I]-altropane SPECT and [18F]-6-flouroDOPA PET scan results which were performed within a three-month interval. PET studies were performed using a PC-4096 scanner (Scanditronix AB, Sweden) with 15 axial slices and resolution of 6 mm FWHM. The SPECT acquisitions were performed on a MultiSPECT gamma camera (Siemens, Hoffman Estates, IL) equipped with fan-beam collimators with an intrinsic resolution of 4.6 FWHM (for Case 1) and a DSI Ceraspect camera with an annular crystal, with resolution of approximately 6.4 mm FWHM (for Case 2).
RESULTS: Both patients, aged 54 and 38 years, had a one-year history of intermittent right hand tremor with right arm rigidity and hypokinesia and bradykinesia on fine finger movements. A significant and sustained improvement of their parkinsonian symptoms was noted using a dopamine agonist. SPECT and PET scans showed non-diagnostic fluoroDOPA PET scans with clear unilateral striatal reduction of tracer uptake contralateral to their parkinsonian side on altropane SPECT scans.
CONCLUSIONS: Altropane SPECT may be an accessible and sensitive imaging modality for detecting early PD. Further and more controlled studies are needed to define its potential role in detecting presymptomatic, early and atypical PD cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687754

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  5 in total

1.  Alteration to Dopaminergic Synapses Following Exposure to Perfluorooctane Sulfonate (PFOS), in Vitro and in Vivo.

Authors:  Rahul Patel; Joshua M Bradner; Kristen A Stout; William Michael Caudle
Journal:  Med Sci (Basel)       Date:  2016-08-16

2.  99mTc-TRODAT-1 SPECT Revealed That Striatal Dopamine Transport Availability Significantly Decreases in Late Mid-Aged Healthy Taiwanese and Then Remains Stable.

Authors:  Skye Hsin-Hsien Yeh; Chi-Jung Tsai; Tsung-Hsun Yu; Yung-Hsiao Chiang; Shinn-Zong Lin; Nan-Jing Peng; Wen-Sheng Huang
Journal:  Clin Nucl Med       Date:  2022-03-01       Impact factor: 7.794

Review 3.  Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.

Authors:  Lie-Hang Shen; Mei-Hsiu Liao; Yu-Chin Tseng
Journal:  J Biomed Biotechnol       Date:  2012-04-10

4.  Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes.

Authors:  Annemarie M M Vlaar; Marinus J P G van Kroonenburgh; Alfons G H Kessels; Wim E J Weber
Journal:  BMC Neurol       Date:  2007-09-01       Impact factor: 2.474

5.  Protocol of a prospective study on the diagnostic value of transcranial duplex scanning of the substantia nigra in patients with parkinsonian symptoms.

Authors:  Annemarie M M Vlaar; Angela E P Bouwmans; Marinus J P G van Kroonenburgh; Werner H Mess; Selma C Tromp; Piet G W M Wuisman; Alfons G H Kessels; Ania Winogrodzka; Wim E J Weber
Journal:  BMC Neurol       Date:  2007-09-04       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.